Photo by nci from unsplash
We agree in principle with our colleagues’ endorsement in this journal of the use of the tropomyosin receptor kinase (TRK) inhibitor LOXO-101 (larotrectinib) in children. Our enthusiasm for the accelerated… Click to show full abstract
We agree in principle with our colleagues’ endorsement in this journal of the use of the tropomyosin receptor kinase (TRK) inhibitor LOXO-101 (larotrectinib) in children. Our enthusiasm for the accelerated deployment of LOXO-101 has been tempered by our experience of multi-TRK inhibitor resistance though. Resistance mutations to LOXO-101 do occur but can be overcome by secondgeneration TRK inhibitors, such as LOXO195 (selitrectinib). We, however, report the emergence of resistance mutations to both firstand second-generation TRK www.nature.com/bjc
Journal Title: British Journal of Cancer
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!